Subscribe
Home
Issues
Online First
2023
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
Categories
Conference Correspondent
ONS 2023 - Multiple Myeloma: Wrap-Up
LBCL 2022 - Year in Review
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Issues
2017 Issues
May 2017 - Vol 10 No 3
TON - May 2017, Vol 10, No 3
From the Editor
From the Editor
TON - May 2017, Vol 10, No 3
The May issue of
The Oncology Nurse-APN/PA
(
TON
) is full of important news and updates for oncology nurses
Read More ›
Moffitt Cancer Center: A Team Approach to Advancing Patient Care
Cancer Center Profile
TON - May 2017, Vol 10, No 3
The H. Lee Moffitt Cancer Center, Tampa, FL, is 1 of 47 National Cancer Institute–designated Comprehensive Care Centers in the United States, and is the only center based in Florida. Care at Moffitt is centered around the patient, and focuses on treating individuals with more common conditions compared with those with rare malignancies.
Read More ›
Hormonal Therapy Associated with Anxiety in Men with Localized Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers
TON - May 2017, Vol 10, No 3
Androgen deprivation therapy (ADT) for the treatment of prostate cancer has adverse effects that may be difficult for men to tolerate.
Read More ›
Prescription Drug Use High Among Survivors of Childhood Cancers
By
Chase Doyle
Survivorship
TON - May 2017, Vol 10, No 3
Childhood cancer therapy can be a double-edged sword: it often leads to a cure, but long after treatment ends, some cancer survivors are still suffering its side effects.
Read More ›
Complexity Associated with Near Miss or Safety Incidents in Patients Treated with Radiotherapy
By
Meg Barbor, MPH
Best Practices
TON - May 2017, Vol 10, No 3
Several treatment- and disease-specific factors are associated with near miss or safety incidents (NMSIs) among patients treated with radiotherapy.
Read More ›
Effectively Communicating with Older Adults with Cancer
By
Meg Barbor, MPH
Best Practices
TON - May 2017, Vol 10, No 3
When interacting with older adults with cancer, using appropriate communication skills is essential to achieving the intended outcome of a conversation.
Read More ›
Multidisciplinary Oral Chemotherapy Clinic Leads to Positive Changes in a Community Hospital
By
Meg Barbor, MPH
Best Practices
TON - May 2017, Vol 10, No 3
Establishing a multidisciplinary oral chemotherapy clinic (MOCC) in a community hospital can reduce emergency department visits, increase patient and provider satisfaction, and lead to earlier recognition of adverse events.
Read More ›
Therapeutic Implications—The Next Era of Genetic Diagnosis
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - May 2017, Vol 10, No 3
PARP inhibitors were the first class of drugs specifically developed to treat BRCA-related tumors by targeting the DNA repair pathway. Although they were developed more than a decade ago, the FDA only
granted approval for their clinical
use a few years ago.
Read More ›
Mechanisms of Response and Resistance to Immunotherapy
By
Chase Doyle
Immunotherapy
TON - May 2017, Vol 10, No 3
Despite remarkable advance in the treatment of cancer through the use of immunotherapy, outcomes still vary, and, for some patients, these regimens provide only a short-term answer.
Read More ›
Shared Antigens Yield Promising Targets for Cancer Prevention
By
Chase Doyle
Immunotherapy
TON - May 2017, Vol 10, No 3
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
Categories
Conference Correspondent
ONS 2023 - Multiple Myeloma: Wrap-Up
LBCL 2022 - Year in Review
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION